PharmaCell B.V. a contract manufacturer for Cellular Therapies and Regenerative Medicine in Europe, has entered into an agreement with TiGenix N.V. to purchase its cell therapy production facility in Sittard-Geleen, The Netherlands. TiGenix is a European cell therapy company with a marketed product, ChondroCelect, for cartilage repair.   PharmaCell will acquire the facility, including its team of employees in production, QC, QA and other functions. ChondroCelect will continue to be manufactured ...